ASML's Trajectory: A Reassessment Amidst Market Dynamics
Finance

ASML's Trajectory: A Reassessment Amidst Market Dynamics

authorBy Strive Masiyiwa
DateJun 01, 2026
Read time3 min

An initial investment in ASML Holding in late 2022 necessitated considerable patience, as the stock's performance remained subdued for a period. This tested the resolve of investors committed to the underlying thesis. However, the landscape dramatically shifted in 2025, witnessing a substantial surge in ASML's stock value. While the company's operational prowess, expansion strategies, product development, and dominant market presence are commendable, these strengths alone do not guarantee an optimal investment. Consequently, a decision was made to retain only half of the shares, with the remainder divested due to concerns regarding its valuation. The company's growth trajectory, while robust, appears insufficient to justify a forward price-to-earnings ratio of 44 times, especially when juxtaposed against competitors offering more attractive valuations and superior growth prospects.

My journey with ASML began in the latter part of 2022, a period that required a steadfast approach as the stock experienced a prolonged phase of limited appreciation. This phase was a true test of confidence in the investment strategy. However, commencing in 2025, ASML's share price embarked on a remarkable upward trend, demonstrating significant gains. This resurgence has been a clear indicator of the company's underlying strength and potential, validating the long-term perspective adopted. The transformation in its market performance underscores the importance of patience in investment, as initial dormancy gave way to substantial returns.

The company's impressive operational framework, strategic growth initiatives, innovative product development, and strong market positioning are undeniable. These elements paint a picture of a robust and forward-thinking organization. However, a critical evaluation reveals that these strong fundamentals do not automatically translate into an attractive investment opportunity at its current valuation. The impressive business attributes must be weighed against market pricing to determine true investment merit. It's a nuanced assessment where inherent quality meets market perception and pricing dynamics.

A significant factor influencing the investment decision was the company's valuation. Despite its strong business profile, the stock's forward price-to-earnings ratio of 44 times raised considerable concerns. This elevated multiple suggests that the market has already priced in a substantial amount of future growth, potentially leaving little room for further upside. Compared to other companies in the market that offer similar or even superior growth rates at more reasonable valuations, ASML appeared to be overvalued. This disparity prompted a strategic adjustment, leading to the sale of a portion of the holdings to mitigate risk associated with high valuation levels.

The decision to reduce exposure was primarily driven by the belief that ASML's growth, while solid, does not warrant its premium valuation. The market currently assigns a forward P/E ratio of 44x, which seems excessively high given its growth profile. There are alternative investment opportunities available that offer either lower valuations for comparable growth or higher growth rates at similar or even lower multiples. This assessment led to a strategic reallocation of capital, aiming to optimize returns by investing in opportunities with a more favorable risk-reward balance. The move reflects a disciplined approach to valuation, prioritizing sustainable growth at a reasonable price.

More Articles
Finance
Roundhill Space & Technology ETF: Unlocking the Future of Space Economy
The Roundhill Space & Technology ETF (MARS) is a compelling investment due to its strategic focus on high-growth companies within the burgeoning space economy. Its top holdings, including Rocket Lab, AST SpaceMobile, and EchoStar, are demonstrating robust growth and improving profitability. The ETF's performance is further bolstered by industry catalysts like falling launch costs and the potential SpaceX IPO, positioning MARS for significant outperformance against its peers and the broader market in the coming years.
By Michele FerreroJun 01, 2026
Finance
Paymentus: A Fintech High-Flier Flying Under The Radar
Paymentus is a prominent player in the electronic bill payment sector, consistently delivering strong financial outcomes. Despite its $3 billion market capitalization, it remains largely unnoticed by many investors. Management continues to perform admirably, ensuring the company's sustained growth and positive trajectory. The shift towards automated, paperless billing provides a robust tailwind, with the market expected to expand at a 12.8% CAGR through 2030.
By Strive MasiyiwaJun 01, 2026
Finance
Hinde Group's Q1 2026 Performance and Market Analysis
Hinde Group's Q1 2026 partner letter details the investment portfolio's performance, which outperformed the S&P 500 despite significant market volatility. Key topics include the impact of the "SaaS-pocalypse" driven by advanced AI coding systems and geopolitical tensions from a military campaign in the Middle East. The letter highlights contributions from Interactive Brokers, Northeast Bank, and Becton Dickinson, alongside portfolio adjustments and an in-depth look at Becton Dickinson's strategic moves.
By Nouriel RoubiniJun 01, 2026
Finance
GE HealthCare Faces Challenges: Earnings Miss and Revised Outlook
GE HealthCare Technologies experienced a significant stock drop following its Q1 2026 earnings report, which revealed a miss on profit expectations and a downward revision of its full-year financial outlook. This setback was primarily attributed to an unexpected $250 million increase in cost inflation. Despite these challenges, the company maintains its organic revenue growth projection at 3.5% and is currently trading at valuation levels not seen in three years, with a forward P/E ratio of 12.8.
By Mariana MazzucatoJun 01, 2026
Finance
Becton, Dickinson: Enhanced Business Focus and Strong Return Potential
This article examines Becton, Dickinson and Company's (BDX) strategic direction, particularly its focus on becoming a more streamlined medical technology leader. It highlights the company's Q1 2026 performance, including currency-neutral revenue growth projections and adjusted diluted EPS targets. The analysis also touches upon the company's valuation, free cash flow deployment, and the primary catalysts for its future re-rating in the market.
By Morgan HouselJun 01, 2026